RxDoctor Payments Data

Flor Rangel, PA

Physician Assistant · Dallas, TXNPI 1689392649

Payments from drug & device makers

$3,222in general payments, 2019–2025

Across 115 payments — averaging $28.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$771
  • AstraZeneca$660
  • Amarin Pharma, Inc.$325
  • Dexcom, Inc.$312
  • AbbVie$304
  • Boehringer Ingelheim$199
  • plus $651 from 12 others

What the payments were for

  • Food & beverage$3,222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,222 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$40,238
Medicare patients
133
Services billed
7,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide50$109,701
JardianceEmpagliflozin58$70,500
OzempicSemaglutide28$50,124
FarxigaDapagliflozin Propanediol36$39,528
VascepaIcosapent Ethyl38$26,286
JanuviaSitagliptin Phosphate21$22,505
TradjentaLinagliptin17$17,519
EliquisApixaban14$17,124
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate11$13,256
XareltoRivaroxaban12$11,056
Tresiba Flextouch U-100Insulin Degludec14$8,367
LinzessLinaclotide12$7,557
Ibandronate Sodium135$5,196
Icosapent Ethyl14$3,439
Wixela InhubFluticasone Propion/Salmeterol11$2,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$771$159,82578 claims
Boehringer IngelheimJardiance, Tradjenta$199$88,01975 claims
AstraZenecaFarxiga$660$39,52836 claims
AbbVieLinzess, Synthroid$304$9,09525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →